Iptacopan
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glomerulonephritis, IGA
Conditions
Glomerulonephritis, IGA, Immunoglobulin A Nephropathy
Trial Timeline
Feb 21, 2025 → Nov 27, 2027
NCT ID
NCT06797518About Iptacopan
Iptacopan is a phase 2 stage product being developed by Novartis for Glomerulonephritis, IGA. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06797518. Target conditions include Glomerulonephritis, IGA, Immunoglobulin A Nephropathy.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05222412 | Pre-clinical | Active |
| NCT06994845 | Phase 3 | Recruiting |
| NCT06903234 | Pre-clinical | Active |
| NCT06797518 | Phase 2 | Recruiting |
| NCT06517758 | Phase 3 | Recruiting |
| NCT05935215 | Phase 3 | Recruiting |
| NCT05630001 | Phase 3 | Completed |
| NCT04889430 | Phase 3 | Active |
| NCT05086744 | Phase 2 | Terminated |
| NCT04747613 | Phase 3 | Active |
| NCT03439839 | Phase 2 | Completed |
Competing Products
8 competing products in Glomerulonephritis, IGA
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| olmesartan medoxomil | Daiichi Sankyo | Phase 2 | 52 |
| infusion of ADR-001 (Mesenchymal stem cell) | Rohto Pharmaceutical | Phase 1 | 33 |
| LNP023 | Novartis | Phase 2 | 52 |
| mycophenolate mofetil orally 1000 mg twice a day (BID) + prednisone 0,5 mg/kg orally on alternate days + intravenous (i.v.) methylprednisolone 1000 mg, total 9 | Roche | Phase 2/3 | 65 |
| ACE inhibitor + statin + Sirolimus (study drug)+ACE inhibitor + statin | Pfizer | Phase 2 | 51 |
| Ramipril | Sanofi | Phase 3 | 76 |
| MOR202 | Biogen | Phase 1/2 | 38 |
| MOR202 | Biogen | Phase 2 | 49 |